Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Get Free Report) saw a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 1,579 shares, an increase of 303.8% from the January 29th total of 391 shares. Based on an average daily volume of 2,424 shares, the days-to-cover ratio is presently 0.7 days. Based on an average daily volume of 2,424 shares, the days-to-cover ratio is presently 0.7 days.
Rocket Pharmaceuticals Stock Up 5.4%
RCKTW opened at $0.03 on Friday. The stock’s 50 day moving average price is $0.02 and its two-hundred day moving average price is $0.03. Rocket Pharmaceuticals has a 12-month low of $0.01 and a 12-month high of $0.09.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.
Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.
Featured Stories
- Five stocks we like better than Rocket Pharmaceuticals
- 3 Signs You May Want to Switch Financial Advisors
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- 1,500 Banks Just Handed the Fed Your Bank Account
- The Biggest IPO Ever… Open to Everyday Folks
- Read this or regret it forever
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
